stockrowTScan Therapeutics, Inc.
TCRX Healthcare Biotechnology
TScan Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.3 million, up 266.7% from fiscal 2024.
- Revenue
- −65.8%
- EPS
- +17.9%
- Free cash flow
- +19.0%
- Total debt
- +1.50%
Quarter to June 2026, against a year earlier
Follow TCRX
Alert me
TScan Therapeutics, Inc. (TCRX) EV/Sales
As of 6 November 2026, TScan Therapeutics, Inc. (TCRX) trades at a EV/Sales of −6.2×. Over the past ten years it has ranged from −34.3× (March 2025) to 52.0× (May 2024); the current reading is higher than 16% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (94.05%) |
| FY2024 | 32.9× | 79.17% |
| FY2023 | 18.4× | — |
| FY2022 | −3.4× | — |
| FY2021 | −10.1× | — |
| FY2020 | −14.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 8.4× | 66.98% |
| Mar 2026 | 5.1× | 157.65% |
| Dec 2025 | 2.0× | (82.54%) |
| Sep 2025 | 11.2× | 515.80% |
| 20 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GUTS Fractyl Health, Inc. compare | −45.9× |
| TCRX TScan Therapeutics, Inc. | −6.2× |
| LPCN Lipocine Inc. compare | −1.5× |
| CASIF CASI Pharmaceuticals Inc. compare | 1.8× |
| BOLT Bolt Biotherapeutics, Inc. compare | 2.5× |
| DARE Dare Bioscience, Inc. compare | 3.9× |
| TVRD Tvardi Therapeutics, Inc. compare | 7.0× |
| BCDA BioCardia, Inc. compare | 28.7× |
| HIND Vyome Holdings, Inc. compare | 124× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)